Intracervical administration of prostaglandin E2-gel prior to therapeutic abortion: a prospective randomized double-blind study.
Forty primigravid women due to undergo first trimester termination of pregnancy were randomly selected for intracervical application of 1 mg prostaglandin E2 in gel or gel only as placebo. In the PGE2-gel group, a marked dilatation of the cervical canal was obtained, with post-gel treatment mean Hegar dilatation of 11.18 mm in that group, compared to 4.4 mm in the control group (P 0.001). Moreover, 16 (80%) patients in the PGE2-gel group had a complete abortion, one (5%) patient had an incomplete abortion and in the remaining three (15%) patients, fetal demise was observed. The mean induction-abortion interval in this group was 7.5 h. In the placebo group, none of the above effects were observed. The only side effect noted was vomiting, which occurred in five (25%) of the patients in the PGE2-gel group. Termination of pregnancy was found to be easier in the PGE2-gel group, compared to the placebo group.
Shalev
E
E
Department of Obstetrics and Gynecology, Central Emek Hospital, Afula, Israel.
Tsabari
A
A
Edelstein
S
S
Weiner
E
E
Zuckerman
H
H
D000032:Abortion, Therapeutic; D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D015232:Dinoprostone / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006801:Humans; D011247:Pregnancy; D011446:Prospective Studies; D011897:Random Allocation
D005782:Gels; D015232:Dinoprostone